|Radius Health Announces Pre-clinical Data for Investigational Drug|
|By David Fowler|
|Thursday, 16 July 2015 18:48|
Biopharmaceutical firm Radius Health Inc. (NASDAQ:RDUS) has confirmed early yet promising preclinical data demonstrating that the investigational drug RAD1901 along with CDK4/6 inhibitors like Pfizer's palbociclib and mTOR inhibitors, such as Novartis' everolimus was able to reduce tumors.
The firm develops new therapeutics for patients with advanced osteoporosis along with other endocrine-mediated diseases such as hormone responsive metastatic breast cancer.
The breast cancer models involving patient derived xenografts, the treatment with RAD 1901 led to marked tumor growth inhibition. However, combination of RAD1901 with agent, everolimus or palbociclib demonstrated anti-tumor activity which was a lot more than the agent alone.
RAD1901 is assessed at big doses as Selective Estrogen Receptor Degrader for use in metastatic breast cancer.
Additionally, Radius also finished pharmacodynamics study in healthy volunteers. All in all, 52 subjects were treated with doses ranging from 200 mg and 1000mg for close to 7 days.
Initial data has shown that doses were well tolerated. A subset of subjects got baseline as well as FES-PET post the 7 days for assessing ER signal attenuation and it can be expected to come out with final results of the study in quarter three of the year.
On the other hand, an abstract named "RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models" having anti-tumor activity as well as therapeutic potential of investigational drug RAD1901 in breast cancer is shown online journal Anti-Cancer Drugs.
Robert E. Ward, President and CEO of Radius Health, opined that the data gives Radius vital insights for evaluating multiple options like combination therapies for seeking acceleration of next phases of clinical development program for RAD1901.
Radius is presently enrolling patients in Phase 1 multicenter as well as dose-escalation study of investigational drug RAD1901 in postmenopausal women.
The study is meant for determining recommended Phase 2 dose of RAD1901 and also has a preliminary evaluation of potential anti-tumor effects.